Gala Global Products Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 1, 2025, 3:53 pm

Quick Insight

Gala Global Products Ltd's current share price of ₹2.97 reflects a market capitalization of ₹16.2 Cr., with concerning financial indicators. The negative net profit margin of -4.49% and operational profit margin of -21.97% suggest operational inefficiencies impacting profitability. Additionally, the low ROCE of 2.28% indicates underutilization of capital. The high level of borrowings at ₹29.01 Cr. compared to reserves of ₹10.74 Cr. raises solvency concerns, evident in the negative interest coverage ratio of -0.29x. Investors should exercise caution due to the company's weak financial position and lack of shareholder information, highlighting significant risks associated with investing in Gala Global Products Ltd.

Competitors of Gala Global Products Ltd

All Competitor Stocks of Gala Global Products Ltd

Quarterly Result

Last Updated: July 16, 2025, 9:28 am

Below is a detailed analysis of the quarterly data for Gala Global Products Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 19.44 Cr.. The value appears strong and on an upward trend. It has increased from 7.06 Cr. (Dec 2024) to 19.44 Cr., marking an increase of 12.38 Cr..
• For Expenses, as of Mar 2025, the value is 23.71 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.68 Cr. (Dec 2024) to 23.71 Cr., marking an increase of 17.03 Cr..
• For Operating Profit, as of Mar 2025, the value is -4.27 Cr.. The value appears to be declining and may need further review. It has decreased from 0.38 Cr. (Dec 2024) to -4.27 Cr., marking a decrease of 4.65 Cr..
• For OPM %, as of Mar 2025, the value is -21.97%. The value appears to be declining and may need further review. It has decreased from 5.38% (Dec 2024) to -21.97%, marking a decrease of 27.35%.
• For Other Income, as of Mar 2025, the value is 0.87 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.87 Cr., marking an increase of 0.86 Cr..
• For Interest, as of Mar 2025, the value is 3.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.26 Cr. (Dec 2024) to 3.05 Cr., marking an increase of 2.79 Cr..
• For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.05 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 0.05 Cr..
• For Profit before tax, as of Mar 2025, the value is -6.45 Cr.. The value appears to be declining and may need further review. It has decreased from 0.08 Cr. (Dec 2024) to -6.45 Cr., marking a decrease of 6.53 Cr..
• For Tax %, as of Mar 2025, the value is -7.91%. The value appears to be improving (decreasing) as expected. It has decreased from 37.50% (Dec 2024) to -7.91%, marking a decrease of 45.41%.
• For Net Profit, as of Mar 2025, the value is -5.94 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Dec 2024) to -5.94 Cr., marking a decrease of 6.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is -1.09. The value appears to be declining and may need further review. It has decreased from 0.01 (Dec 2024) to -1.09, marking a decrease of 1.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:21 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:15 pm

Below is a detailed analysis of the balance sheet data for Gala Global Products Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 27.29 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 27.29 Cr..
• For Reserves, as of Mar 2025, the value is 10.74 Cr.. The value appears to be declining and may need further review. It has decreased from 15.23 Cr. (Mar 2024) to 10.74 Cr., marking a decrease of 4.49 Cr..
• For Borrowings, as of Mar 2025, the value is 29.01 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 25.71 Cr. (Mar 2024) to 29.01 Cr., marking an increase of 3.30 Cr..
• For Other Liabilities, as of Mar 2025, the value is 69.98 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 40.48 Cr. (Mar 2024) to 69.98 Cr., marking an increase of 29.50 Cr..
• For Total Liabilities, as of Mar 2025, the value is 137.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.71 Cr. (Mar 2024) to 137.02 Cr., marking an increase of 28.31 Cr..
• For Fixed Assets, as of Mar 2025, the value is 14.07 Cr.. The value appears to be declining and may need further review. It has decreased from 14.21 Cr. (Mar 2024) to 14.07 Cr., marking a decrease of 0.14 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 122.95 Cr.. The value appears strong and on an upward trend. It has increased from 94.50 Cr. (Mar 2024) to 122.95 Cr., marking an increase of 28.45 Cr..
• For Total Assets, as of Mar 2025, the value is 137.02 Cr.. The value appears strong and on an upward trend. It has increased from 108.71 Cr. (Mar 2024) to 137.02 Cr., marking an increase of 28.31 Cr..

However, the Borrowings (29.01 Cr.) are higher than the Reserves (10.74 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Key Financial Ratios

After reviewing the key financial ratios for Gala Global Products Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -0.82. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to -0.82, marking a decrease of 0.86.
• For Diluted EPS (Rs.), as of Mar 25, the value is -0.82. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to -0.82, marking a decrease of 0.86.
• For Cash EPS (Rs.), as of Mar 25, the value is -0.79. This value is below the healthy minimum of 3. It has decreased from 0.07 (Mar 24) to -0.79, marking a decrease of 0.86.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.97. It has decreased from 7.79 (Mar 24) to 6.97, marking a decrease of 0.82.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.97. It has decreased from 7.79 (Mar 24) to 6.97, marking a decrease of 0.82.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.65. It has decreased from 13.79 (Mar 24) to 7.65, marking a decrease of 6.14.
• For PBDIT / Share (Rs.), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 2. It has decreased from 0.18 (Mar 24) to -0.19, marking a decrease of 0.37.
• For PBIT / Share (Rs.), as of Mar 25, the value is -0.22. This value is below the healthy minimum of 0. It has decreased from 0.15 (Mar 24) to -0.22, marking a decrease of 0.37.
• For PBT / Share (Rs.), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 0. It has decreased from 0.05 (Mar 24) to -0.81, marking a decrease of 0.86.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -0.82. This value is below the healthy minimum of 2. It has decreased from 0.03 (Mar 24) to -0.82, marking a decrease of 0.85.
• For PBDIT Margin (%), as of Mar 25, the value is -2.60. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -2.60, marking a decrease of 3.94.
• For PBIT Margin (%), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 10. It has decreased from 1.10 (Mar 24) to -2.94, marking a decrease of 4.04.
• For PBT Margin (%), as of Mar 25, the value is -10.67. This value is below the healthy minimum of 10. It has decreased from 0.36 (Mar 24) to -10.67, marking a decrease of 11.03.
• For Net Profit Margin (%), as of Mar 25, the value is -10.75. This value is below the healthy minimum of 5. It has decreased from 0.27 (Mar 24) to -10.75, marking a decrease of 11.02.
• For Return on Networth / Equity (%), as of Mar 25, the value is -11.81. This value is below the healthy minimum of 15. It has decreased from 0.49 (Mar 24) to -11.81, marking a decrease of 12.30.
• For Return on Capital Employeed (%), as of Mar 25, the value is -1.58. This value is below the healthy minimum of 10. It has decreased from 1.39 (Mar 24) to -1.58, marking a decrease of 2.97.
• For Return On Assets (%), as of Mar 25, the value is -3.27. This value is below the healthy minimum of 5. It has decreased from 0.19 (Mar 24) to -3.27, marking a decrease of 3.46.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has increased from 0.39 (Mar 24) to 0.54, marking an increase of 0.15.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.76. This value is within the healthy range. It has increased from 0.60 (Mar 24) to 0.76, marking an increase of 0.16.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.34. It has decreased from 0.67 (Mar 24) to 0.34, marking a decrease of 0.33.
• For Current Ratio (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 1.92 (Mar 24) to 1.74, marking a decrease of 0.18.
• For Quick Ratio (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.71, marking a decrease of 0.15.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 18.25. This value exceeds the healthy maximum of 8. It has increased from 6.24 (Mar 24) to 18.25, marking an increase of 12.01.
• For Interest Coverage Ratio (X), as of Mar 25, the value is -0.29. This value is below the healthy minimum of 3. It has decreased from 1.04 (Mar 24) to -0.29, marking a decrease of 1.33.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.34. This value is below the healthy minimum of 3. It has decreased from 0.78 (Mar 24) to -0.34, marking a decrease of 1.12.
• For Enterprise Value (Cr.), as of Mar 25, the value is 48.16. It has increased from 41.75 (Mar 24) to 48.16, marking an increase of 6.41.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has increased from 0.55 (Mar 24) to 1.15, marking an increase of 0.60.
• For EV / EBITDA (X), as of Mar 25, the value is -44.26. This value is below the healthy minimum of 5. It has decreased from 41.26 (Mar 24) to -44.26, marking a decrease of 85.52.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.45, marking an increase of 0.24.
• For Price / BV (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has increased from 0.37 (Mar 24) to 0.50, marking an increase of 0.13.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.45, marking an increase of 0.24.
• For EarningsYield, as of Mar 25, the value is -0.23. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.23, marking a decrease of 0.24.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness